Chronische Hepatitis

  • Ulrich R. Fölsch
  • Ulrich Junge
Part of the Kliniktaschenbücher book series (KTB)

Zusammenfassung

Chronische Hepatitis nennt man nach internationaler Übereinkunft länger als 6 Monate andauernde, histologisch und durch entsprechende Laborparameter nachweisbare entzündliche Veränderungen der Leber.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Arnold W (1980) Systematik und Verlauf der chronischen Hepatitis. Intern Welt 7: 253–262Google Scholar
  2. 2.
    Czaja AJ, Ludwig J, Baggenstoss AH et al. (1981) Corticosteroid-treated chronic active hepatitis in remission. Uncertain prognosis of chronic persistent hepatitis. N Engl J Med 304: 5–9PubMedCrossRefGoogle Scholar
  3. 3.
    Copenhagen Study Group for Liver Diseases (1969) Effect of prednisone on the survival of patients with cirrhosis of the liver. Lancet 1: 119–121Google Scholar
  4. 4.
    Soloway RD, Summerskill WHJ, Baggenstoss AH et al. (1972) Clinical, biochemical and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 63: 820–833PubMedGoogle Scholar
  5. 5.
    Murray-Lyon IM, Stern RB, Williams R (1973) Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1: 735–737PubMedCrossRefGoogle Scholar
  6. 6.
    Meyer zum Büschenfelde KH (1978) Studie der Paul-Ehrlich-Gesellschaft: Immunsuppressive Therapie der HBs-Antigen-positiven und -ne-gativen chronisch-aktiven Hepatitis. Dtsch Med Wochenschr 103: 887–892PubMedCrossRefGoogle Scholar
  7. 7.
    Lam KC, Lai CL, Ng RP et al. (1981) Deleterious effect of prednisolone in HBSAG-positive chronic active hepatitis. N Engl J Med 304: 380–386PubMedCrossRefGoogle Scholar
  8. 8.
    Summerskill WHJ, Korman MG, Ammon HV Baggenstoss AH (1975) Prednison for chronic liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 16: 876–883PubMedCrossRefGoogle Scholar
  9. 9.
    Kinlen LJ, Sheil AGR, Peto J, Doll R (1979) Collaborative United King-dom-Australasian study of cancer im patients treated with immunsuppres-sive drugs Br Med J 2: 1461–1466Google Scholar
  10. 10.
    Scullard GH, Robinson WS Merigan TL Gregory PB (1979) The effect of immunosuppressive therapy on hepatitis B viral infection in patients with chronic hepatitis. Gastroenterology 77: A 40Google Scholar
  11. 11.
    Pape GR, Paumgartner G (1980) Therapie der chronischen Hepatitis. In-tern Welt 8: 304–309Google Scholar
  12. 12.
    Chadwick RG, Bassendine MF Crawford EM, Thomas HC Sherlock S (1978) HBSAG-positive chronic liver disease: inhibition of DNA polymerase activity by vidarabine. Br Med J 2: 531–533PubMedCrossRefGoogle Scholar
  13. 13.
    Weimar W, Heijtink RA, ten Kate FJP et al. (1980) Double-blind study of leucocyte interferon administration in chronic HBsAg-positive hepatitis. Lancet 1: 336 - 338PubMedCrossRefGoogle Scholar
  14. 14.
    Junge U (1981) Chronisch persistierende Hepatitis: Eine gutartige Erkrankung? Inn Med 8: 116–117Google Scholar
  15. 15.
    Kirk AP, Jain S, Pocock S et al. (1980) Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 21: 78–83PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1982

Authors and Affiliations

  • Ulrich R. Fölsch
    • 1
  • Ulrich Junge
    • 2
  1. 1.Medizinische Klinik und PoliklinikGöttingenDeutschland
  2. 2.Zentrum Innere MedizinUniversität UlmUlmDeutschland

Personalised recommendations